PlainRecalls
FDA Drug Critical Class I Terminated

Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01

Reported: March 21, 2018 Initiated: February 7, 2018 #D-0596-2018

Product Description

Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01

Reason for Recall

Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.

Details

Recalling Firm
Pfizer Inc.
Units Affected
53600 vials
Distribution
Nationwide in the USA
Location
New York, NY

Frequently Asked Questions

What product was recalled?
Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01. Recalled by Pfizer Inc.. Units affected: 53600 vials.
Why was this product recalled?
Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 21, 2018. Severity: Critical. Recall number: D-0596-2018.